ATE554169T1 - Smad7-inhibitoren zur behandlung von krankheiten des zns - Google Patents
Smad7-inhibitoren zur behandlung von krankheiten des znsInfo
- Publication number
- ATE554169T1 ATE554169T1 AT02790321T AT02790321T ATE554169T1 AT E554169 T1 ATE554169 T1 AT E554169T1 AT 02790321 T AT02790321 T AT 02790321T AT 02790321 T AT02790321 T AT 02790321T AT E554169 T1 ATE554169 T1 AT E554169T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cns diseases
- smad7 inhibitors
- diseases
- disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101700026522 SMAD7 Proteins 0.000 title abstract 2
- 102000049873 Smad7 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126140 | 2001-11-02 | ||
| PCT/EP2002/012221 WO2003037368A2 (en) | 2001-11-02 | 2002-10-31 | Smad7 inhibitors for the treatment of cns diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE554169T1 true ATE554169T1 (de) | 2012-05-15 |
Family
ID=8179155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02790321T ATE554169T1 (de) | 2001-11-02 | 2002-10-31 | Smad7-inhibitoren zur behandlung von krankheiten des zns |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7700572B2 (de) |
| EP (1) | EP1456380B1 (de) |
| AT (1) | ATE554169T1 (de) |
| AU (1) | AU2002363182A1 (de) |
| CY (1) | CY1112932T1 (de) |
| DK (1) | DK1456380T3 (de) |
| ES (1) | ES2388968T3 (de) |
| PT (1) | PT1456380E (de) |
| SI (1) | SI1456380T1 (de) |
| WO (1) | WO2003037368A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1456380B1 (de) * | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7-inhibitoren zur behandlung von krankheiten des zns |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| RU2593939C2 (ru) | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| US9468649B2 (en) * | 2008-12-05 | 2016-10-18 | The Regents Of The University Of California | Methods of treating epilepsy with transforming growth factor beta inhibitors |
| US9005968B2 (en) | 2009-10-16 | 2015-04-14 | The Scripps Research Institute | Induction of pluripotent cells |
| EP2553086B1 (de) | 2010-03-31 | 2017-04-19 | The Scripps Research Institute | Umprogrammierung von zellen |
| AU2011349446C1 (en) | 2010-12-22 | 2016-01-21 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
| ES2392862B1 (es) * | 2011-06-02 | 2013-11-05 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Tgf-beta y/o smad3 como marcadores de diagnóstico y/o pronóstico de alfa-sinucleinopatías |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| MX370149B (es) * | 2012-04-18 | 2019-12-03 | Nogra Pharma Ltd | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA3001917A1 (en) | 2015-10-16 | 2017-04-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| WO2021237067A1 (en) * | 2020-05-22 | 2021-11-25 | President And Fellows Of Harvard College | Interferon- inducing oligonucleotide duplexes and methods of use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| AU678769B2 (en) * | 1992-07-27 | 1997-06-12 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
| US6884787B2 (en) * | 2001-07-14 | 2005-04-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of transforming growth factor-beta 3 expression |
| CA2148465C (en) * | 1992-11-06 | 1999-11-02 | Minenobu Okayama | Oral pharmaceutical preparation releasable in the lower digestive tract |
| US20020177568A1 (en) * | 1992-12-07 | 2002-11-28 | Stinchcomb Dan T. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B |
| US6455689B1 (en) * | 1993-04-30 | 2002-09-24 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-oligonucleotides for transforming growth factor-β (TGF-β) |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| AU725192B2 (en) * | 1996-02-16 | 2000-10-05 | Brigham And Women's Hospital | Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
| US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| AU721549B2 (en) | 1996-12-11 | 2000-07-06 | Bristol-Myers Squibb Company | Prokaryotic two-hybrid system |
| JPH10295381A (ja) * | 1997-04-23 | 1998-11-10 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 新規シグナル伝達因子、およびそれをコードする遺伝子 |
| CA2290040A1 (en) * | 1997-05-20 | 1998-11-26 | Ludwig Institute For Cancer Research | Smad7 and uses thereof |
| WO1999001579A1 (en) * | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| JPH11335269A (ja) * | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
| WO2000002911A2 (en) | 1998-07-10 | 2000-01-20 | Curagen Corporation | INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| US6479465B2 (en) * | 1999-03-24 | 2002-11-12 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating colitis using STAT-4 anti-sense oligonucleotides |
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| US20020147140A1 (en) * | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| WO2001062207A2 (en) * | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| KR20020097200A (ko) * | 2000-03-21 | 2002-12-31 | 엘리트라 파마슈티컬즈, 인코포레이티드 | 원핵세포에서의 필수유전자의 동정 |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| EP1456380B1 (de) * | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7-inhibitoren zur behandlung von krankheiten des zns |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| AU2003296944A1 (en) * | 2002-12-10 | 2004-06-30 | George Koob | A method for treatment of drug addiction and for screening of pharmaceutical agents therefor |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US20040265833A1 (en) * | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
| US20070155685A1 (en) * | 2004-02-27 | 2007-07-05 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
| US20080312093A1 (en) * | 2005-11-04 | 2008-12-18 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| WO2009151600A2 (en) * | 2008-06-10 | 2009-12-17 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US8110355B2 (en) * | 2009-02-20 | 2012-02-07 | GenRemedy, LLC | Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
-
2002
- 2002-10-31 EP EP02790321A patent/EP1456380B1/de not_active Expired - Lifetime
- 2002-10-31 US US10/494,333 patent/US7700572B2/en not_active Expired - Fee Related
- 2002-10-31 AT AT02790321T patent/ATE554169T1/de active
- 2002-10-31 DK DK02790321.0T patent/DK1456380T3/da active
- 2002-10-31 AU AU2002363182A patent/AU2002363182A1/en not_active Abandoned
- 2002-10-31 PT PT02790321T patent/PT1456380E/pt unknown
- 2002-10-31 SI SI200230992T patent/SI1456380T1/sl unknown
- 2002-10-31 ES ES02790321T patent/ES2388968T3/es not_active Expired - Lifetime
- 2002-10-31 WO PCT/EP2002/012221 patent/WO2003037368A2/en not_active Ceased
-
2009
- 2009-09-23 US US12/565,629 patent/US20110207795A1/en not_active Abandoned
-
2012
- 2012-07-09 CY CY20121100612T patent/CY1112932T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1456380E (pt) | 2012-07-23 |
| EP1456380B1 (de) | 2012-04-18 |
| EP1456380A2 (de) | 2004-09-15 |
| WO2003037368A3 (en) | 2004-03-11 |
| US20110207795A1 (en) | 2011-08-25 |
| DK1456380T3 (da) | 2012-07-30 |
| US7700572B2 (en) | 2010-04-20 |
| CY1112932T1 (el) | 2016-04-13 |
| AU2002363182A1 (en) | 2003-05-12 |
| WO2003037368A2 (en) | 2003-05-08 |
| US20050119203A1 (en) | 2005-06-02 |
| SI1456380T1 (sl) | 2012-11-30 |
| ES2388968T3 (es) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| ATE452884T1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE323490T1 (de) | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung | |
| IL162384A0 (en) | Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| MXPA05013226A (es) | Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas. | |
| ATE443044T1 (de) | Tace inhibitoren | |
| MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| HUP0103712A2 (hu) | Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk | |
| ATE295724T1 (de) | Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten |